Methods for the reduction or ablation of gene function

  • Matthew G. F. Sharp
  • John J. Mullins

Abstract

The ability to reduce the expression of specific genes by inhibiting their expression directly or by interfering with the gene product is desirable for both therapeutic and experimental reasons. With advances in gene therapy, strategies are being developed to replace defective genes or introduce exogenous inhibitors of gene expression such as antisense RNAs or ribozyme sequences, which are targeted at specific messenger (m)RNAs. In basic biomedical research, gene knockout techniques and antisense RNAs are being used experimentally to gain further understanding of developmental and physiologi­cal processes and to identify the function of specific genes. These approaches allow the investigation of individual genes in the context of a complex living organism, and can identify a causal relationship between a particular gene mutation and a disease phenotype. The methodologies appropriate for the experimental manipulation of gene expression in living organisms can be divided broadly into two categories: (a) gene targeting, whereby a gene is modified by the integration of a homologous DNA construct, such that the endogenous gene is no longer able to give rise to a functional, stable mRNA and (b) the reduction in, or loss of, the function of a geneproduct, which can be achieved via various antisense inhibition strategies, the introduction of point mutations, or the expression of dominantly-acting mutated proteins

Keywords

Cystic Fibrosis Embryonic Stem Cell Selectable Marker Internal Ribosome Entry Site Mouse Embryonic Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bradley A, Hasty P, Davis A, Ramirez-Solis R:Modifying the mouse: design and desire. Bio/Technology 1992,10: 534–539.PubMedCrossRefGoogle Scholar
  2. 2.
    lannaccone PM, Taborn GU, Garton RL, Caplice MD, Brenin DR:Pluripotent embryonic stem cells from the rat are capable of producing chimeras. Dev Biol 1994,163: 288–292.CrossRefGoogle Scholar
  3. 3.
    Thomas KR, Folger KR, Capecchi MR:High frequency targeting of genes to specific sites in the mammalian genome. Cell 1986,44: 419–428.PubMedCrossRefGoogle Scholar
  4. 4.
    Capecchi MR:Altering the genome by homologous recombination. Science 1989,244:1288–1292.PubMedCrossRefGoogle Scholar
  5. 5.
    Hasty P, Rivera PJ, Chang C, Bradley A:Target frequency and integration pattern for insertion and replacement vectors in embryonic stem cells. Mol Cell Biol 1991,11: 4509–4517.PubMedGoogle Scholar
  6. 6.
    Hasty P, Rivera PJ, Bradley A:The length of homology required for gene targeting in embryonic stem cells. Mol Cell Biol 1991,11: 5586–5591.PubMedGoogle Scholar
  7. 7.
    Thomas KR, Capecchi MR:Site–directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987,51: 503–512.PubMedCrossRefGoogle Scholar
  8. 8.
    Deng CX, Capecchi MR:Re-examination of gene targeting frequency as a function of the extent of homology between the targeting vector and the target locus. Mol Cell Biol 1992,12: 3365–3371.PubMedGoogle Scholar
  9. 9.
    Buerstedde JM, Takeda S:Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell 199167: 179–188.PubMedCrossRefGoogle Scholar
  10. 10.
    te Riele H, Maandag ER, Berns A:Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc Natl Acad Sci Usa 199189: 5128–5132.CrossRefGoogle Scholar
  11. 11.
    Zheng H, Wilson JH:Gene targeting in normal and amplified cell lines. Nature 1990,344: 170–173.PubMedCrossRefGoogle Scholar
  12. 12.
    Li E, Bestor TH, Jaenisch R:Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992,69: 915–926.PubMedCrossRefGoogle Scholar
  13. 13.
    Mansour SL, Thomas KR, Capecchi MR:Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 1988,336: 348–352.PubMedCrossRefGoogle Scholar
  14. 14.
    Yagi T, Ikawa Y, Yoshida K, Shigetani Y, Takeda N, Mabuchi I, et al.:Homologous recombination at c-fyn locus of mouse embryonic stem cells with use of diphtheria toxin A-fragment gene in negative selection. Proc Natl Acad Sci Usa 1990,87: 9918–9922.PubMedCrossRefGoogle Scholar
  15. 15.
    Valancius V, Smithies O:Testing an ’in-out’ targeting procedure for making subtle genomic modifications in mouse embryonic stem cells. Mol Cell Biol 1991,11: 1402–1408.PubMedGoogle Scholar
  16. 16.
    Hasty P, Ramirez-Solis R, Krumlauf R, Bradley A:Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells. Nature 1991,350: 243–246.PubMedCrossRefGoogle Scholar
  17. 17.
    Askew GR, Doetschman T, Lingrel JB:Site-directed point mutations in embryonic stem cells: a gene-targeting tag-and-exchange strategy. Mol Cell Biol 1993,13: 4115–4124.PubMedGoogle Scholar
  18. 18.
    van Deursen J, Lovell-Badge R, Oerlemans F, Schepens J, Wieringa B:Modulation of gene activity by consecutive gene targeting of one creatine kinase M allele in mouse embryonic stem cells. Nucleic Acids Res 1991,19: 2637–2643.PubMedCrossRefGoogle Scholar
  19. 19.
    Davis AC, Wims M, Bradley A:Investigation of coelectropoation as a method for introducing small mutations into embryonic stem cells. Mol Cell Biol 1992,12: 2769–2776.PubMedGoogle Scholar
  20. 20.
    Koller BH, Kim HS, Latour AM, Brigman K, Boucher RC Jr, Scambler P, et al.:Toward an animal model of cystic fibrosis: targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells. Proc Natl Acad Sci Usa 1991,88: 10730–10734.PubMedCrossRefGoogle Scholar
  21. 21.
    Dorin JR, Dickinson P, Alton EWFW, Smith SN, Geddes DM, Stevenson BJ, et al.:Cystic fibrosis in the mouse by targeted insertional mutagenesis. Nature 1992,359: 211–215.PubMedCrossRefGoogle Scholar
  22. 22.
    Clarke LL, Grubb BR, Gabriel SE, Smithies O, Koller BH, Boucher RC:Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis. Science 1992,257: 1125–1128.PubMedCrossRefGoogle Scholar
  23. 23.
    Colledge WH, Ratcliff R, Foster D, Williamson R, Evans MJ:Cystic fibrosis mouse with intestinal obstruction. Lancet 1992,340: 680–680PubMedCrossRefGoogle Scholar
  24. 24.
    Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, et al.:An animal model for cystic fibrosis made by gene targeting. Science 1992,257: 1083–1088.PubMedCrossRefGoogle Scholar
  25. 25.
    Piedrahati JA, Zhang SH, Hagaman JR, Oliver PM, Maeda M:Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci Usa 1992,89: 4471–4475.CrossRefGoogle Scholar
  26. 26.
    Zhang SH, Reddick RL, Piedrahita JA, Maeda N:Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992,258: 468–471.PubMedCrossRefGoogle Scholar
  27. 27.
    Plump AS, Smith JD, Hayek T, Aaltosetala K, Walsh A, Verstuyft JG, et al.:Severe hypercholesterolemia and atherosclerosis in apolipoprotein-e-deficient mice created by homologous recombination in ES cells. Cell 1992,71: 343–353.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang SH, Reddick RL, Burkey B, Maeda N:Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein-E gene disruption. J Clin Invest 1994,94: 937–945.PubMedCrossRefGoogle Scholar
  29. 29.
    Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS:The two-receptor model of lipoprotein clearance: tests of the hypothesis in ’knockout’ mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci Usa 1994,91: 4431–4435.PubMedCrossRefGoogle Scholar
  30. 30.
    Zheng H, Hasty P, Brenneman MA, Grompe M, Gibbs RA, Wilson JH, et al.:Fidelity of targeted recombination in human fibroblasts and murine embryonic stem cells. Proc Natl Acad Sci Usa 1991,88: 8067–8071.PubMedCrossRefGoogle Scholar
  31. 31.
    Williamson DJ, Hooper ML, Melton DW:Mouse models of hypoxanthine phosphoribosyltransferase deficiency. J Inherit Metab Dis 1992,15: 665–673.PubMedCrossRefGoogle Scholar
  32. 32.
    Wu CL, Melton DW:Production of a model for Lesclv-Nyhan syndrome in hypoxanthine phosphoribosyltransferase-deficient mice. Nature Genet 1993,3: 235–240.PubMedCrossRefGoogle Scholar
  33. 33.
    Mountford P, Zevnik B, Duwel A, Nichols J, Li M, Dani C, et al.:Dicistronic targeting constructs: Reporters and modifiers of mammalian gene expression. Proc Natl Acad Sci Usa 1994,91: 4303–4307.PubMedCrossRefGoogle Scholar
  34. 34.
    Jeannotte L, Ruiz JC, Robertson EJ:Low level of Hox1.3 gene expression does not preclude the use of promoterless vectors to generate a targeted gene disruption. Mol Cell Biol 1991,11: 5578–5585.PubMedGoogle Scholar
  35. 35.
    Friedrich G, Soriano P:Promoter traps in embryonic stem-cells: a genetic screen to identify and mutate developmental genes in mice. Genes Develop 1991,5: 1513–1523.PubMedCrossRefGoogle Scholar
  36. 36.
    Mountford PS, Smith AG:Internal ribosome entry sites and dicistronic RNAs in mammalian transgenesis. Trends Genet 1995,11: 179–184.PubMedCrossRefGoogle Scholar
  37. 37.
    Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, et al.:Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994,269: 31334–31337.PubMedGoogle Scholar
  38. 38.
    Kim H-S, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, et al.:Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci Usa 1995,92: 2735–2739.PubMedCrossRefGoogle Scholar
  39. 39.
    Krege JH, John SWM, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, et al.:Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995,375: 146–148.PubMedCrossRefGoogle Scholar
  40. 40.
    Ito M, Oliverio Ml, Mannon PJ, Best CF, Maeda N, Smithies O, et al.:Regulation of blood-pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci Usa 1995,92: 3521–3525.PubMedCrossRefGoogle Scholar
  41. 41.
    Smithies O, Kim HS:Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc Natl Acad Sci Usa 1994,91:3612–3615.PubMedCrossRefGoogle Scholar
  42. 42.
    Miller CCJ, Mcpheat JC, Potts WJ:Targeted integration of the renid locus in mouse embryonic stem cells. Proc Natl Acad Sci Usa 1992,89: 5020–5024.PubMedCrossRefGoogle Scholar
  43. 43.
    Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, et al.:Elevated blood-pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994,368: 703–710.PubMedCrossRefGoogle Scholar
  44. 44.
    John SWM, Krege JH, Oliver PM, Hagaman Jr, Hodgin JB, Pang SC, et al.:Genetic decreases in atrial-natriuretic-peptide and salt-sensitive hypertension. Science 1995,267: 679–681.PubMedCrossRefGoogle Scholar
  45. 45.
    Behringer RR, Mathews LS, Palmiter RD, Brinster RL:Dwarf mice produced by genetic ablation of growth hormone-expressing cells. Genes Dev 1988,2: 453–461.PubMedCrossRefGoogle Scholar
  46. 46.
    Borrelli E, Heyman RA, Arias C, Sawchenko PE, Evans RM:Transgenic mice with inducible dwarfism. Nature 1989,339: 538–541.PubMedCrossRefGoogle Scholar
  47. 47.
    Breitman ML, Rombola H, Maxwell IH, Klintworth GK, Bernstein A:Genetic ablation in transgenic mice with an attenuated diphtheria toxin A gene. Mol Cell Biol 1990,10: 474–479.PubMedGoogle Scholar
  48. 48.
    Palmiter RD, Behringer RR, Quaife CJ, Maxwell F, Maxwell IH, Brinster RL:Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene. Cell 1987,50: 435–443.PubMedCrossRefGoogle Scholar
  49. 49.
    Moffat KG, Gould JH, Smith HK, O’Kane CJ:Inducible cell ablation in Drosophila by cold-sensitive ricin A chain. Development 1992,114: 681–687.PubMedGoogle Scholar
  50. 50.
    Inouye M:Antisense RNA: its functions and applications in gene regulation: a review. Gene 1988,72:25–34.PubMedCrossRefGoogle Scholar
  51. 51.
    Wagner RW:Gene inhibition using antisense oligodeoxynucleotides. Nature 1994,372:333–335.PubMedCrossRefGoogle Scholar
  52. 52.
    Stein CA, Cheng Y-C:Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science 1993,261: 1004–1012.PubMedCrossRefGoogle Scholar
  53. 53.
    Agrawal S, Temsamani J, Tang JY:Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 1991,88: 7595–7599.PubMedCrossRefGoogle Scholar
  54. 54.
    Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, et al.:Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993,90: 8474–8478.PubMedCrossRefGoogle Scholar
  55. 55.
    Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, et al.:Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J Clin. Invest 1994,93: 1458–1464.PubMedCrossRefGoogle Scholar
  56. 56.
    Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD:Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992,359: 67–70.PubMedCrossRefGoogle Scholar
  57. 57.
    Clouston WM, Lloyd CJ, Richards RL:Inducible anti-sense RNA for angiotensinogen in stably transformed hepatoma cell lines. J Mol Endocrinol 1990,4: 107–117.PubMedCrossRefGoogle Scholar
  58. 58.
    Cumin F, Asselbergs F, Lartigot M, Felder E:Modulation of human prorenin gene expression by antisense oligonucleotides in transfected CHO cells. Eur J Biochem 1993,212: 347–54.PubMedCrossRefGoogle Scholar
  59. 59.
    Wielbo D, Sernia C, Gyurko R, Phillips ML:Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 1995,25: 314–319.PubMedGoogle Scholar
  60. 60.
    Phillips ML, Wielbo D, Gyurko R:Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes. Kidney Int 1994,46: 1554–1556.PubMedCrossRefGoogle Scholar
  61. 61.
    Tomita N, Morishita R, Higaki J, Aoki M, Nakamura Y, Mikami H, et al.:Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 1995,26: 131–136.PubMedGoogle Scholar
  62. 62.
    Cook JL, Bhandaru S, Giardina JF, Claycomb WC, Re RN:Identification and antisense inhibition of a renin-angiotensin system, in transgenic cardiomyocytes. Am J Physiol Heart Circ Physiol 1995,37: H1471–H1482.Google Scholar
  63. 63.
    Kupfer J, Duong A, Litvack F, Eigler N, Forrester J, Rubin S:Modulation of angiotensin-receptors by antisense-effects on cellular metabolism and proliferation. Circulation 1993,88: 473–473.Google Scholar
  64. 64.
    Kupfer J, Doung A, Litvack F, Forrester J, Rubin S:Modulation of angiotensin-receptors by antisense-effects on receptor-binding. Circulation 1993,88: 473–473.Google Scholar
  65. 65.
    Lu D, Raizada MK:Delivery of angiotensin-ll type-1 receptor antisense inhibits angiotensin action in neurons from hypertensive rat brain. Proc Natl Acad Sci USA 1995,92: 2914–2918.PubMedCrossRefGoogle Scholar
  66. 66.
    Lu D, Yu K, Raizada MK:Retrovirus-mediated transfer of an angiotensin type-l receptor (AT(1)-R) antisense sequence decreases AT(1)-Rs and angiotensin-ll action in astroglial and neuronal cells in primary cultures from the brain. Proc Natl Acad Sci USA 1995,92: 1162–1166.PubMedCrossRefGoogle Scholar
  67. 67.
    Pedrazzini T, Cousin P, Aubert JF, Brunner HR:Transient inhibition of angiotensinogen production in transgenic mice bearing an antisense angiotensinogen gene. Kidney Int 1995,47: 1638–1646.PubMedCrossRefGoogle Scholar
  68. 68.
    Wagner EGH, Simons RW:Antisense RNA control in bacteria, phages, and plasmids. Annu Rev Microbiol 1994,48: 713–742.PubMedCrossRefGoogle Scholar
  69. 69.
    . Bass BL, Weintraub H:A developmentally regulated activity that unwinds RNA duplexes. Cell 1987,48: 607–613.PubMedCrossRefGoogle Scholar
  70. 70.
    Bass BL, Weintraub H:An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 1988,55: 1089–1098.PubMedCrossRefGoogle Scholar
  71. 71.
    Kim U, Nishikura K:Double-stranded RNA adenosine deaminase as a potential mammalian RNA editing factor. Sem Cell Biol 1993,4: 285–293.CrossRefGoogle Scholar
  72. 72.
    Munir Ml, Rossiter BJ, Caskey CT:Antisense RNA production in transgenic mice. Somat Cell Mol Genet 1990,16: 383–394.PubMedCrossRefGoogle Scholar
  73. 73.
    Katsuki M, Sato M, Kimura M, Yokoyama M, Kobayashi K, Nomura T:Conversion of normal behavior to shiverer by myelin basic protein antisense cDNA in transgenic mice. Science 1988,241: 593–595.PubMedCrossRefGoogle Scholar
  74. 74.
    Pepin M-C, Pothier F, Barden N:Impaired type II glucocorticoid-receptor function in mice bearing antisense RNA transgene. Nature 1992,355: 725–728.PubMedCrossRefGoogle Scholar
  75. 75.
    Efrat S, Leiser M, Wu YJ, Fusco-DeMane D, Emran OA, Surana M, et al.:Ribozyme-mediated attenuation of pancreatic 0- cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin-secretion. Proc Natl Acad Sci USA 1994,91: 2051–2055.PubMedCrossRefGoogle Scholar
  76. 76.
    Matsumoto K, Kakidani H, Takahashi A, Nakagata N, Anzai M, Matsuzaki Y, et al.:Growth retardation in rats whose growth hormone gene expression was suppressed by antisense RNA transgene. Mol Reprod Dev 1993,36: 53–58.PubMedCrossRefGoogle Scholar
  77. 77.
    Moxham CM, Hod Y, Malbon CC:Induction of Gai2-specific antisense RNA in vivo inhibits neonatal growth. Science 1993,260: 991–995.PubMedCrossRefGoogle Scholar
  78. 78.
    L’Huillier PJ, Bellamy AR, Davis SR:Cytoplasmic delivery of ribozymes leads to efficient reduction in α-lactalbumin mRNA levels in C127I mouse cells. EMBO J 1992,11: 4411–4418.PubMedGoogle Scholar
  79. 79.
    Potter PM, Harris LC, Remack JS, Edwards CC, Brent TP:Ribozyme-mediated modulation of human 06-methylguanine-DNA methyltransferase expression. Cancer Res 1993,53: 1731–1734.PubMedGoogle Scholar
  80. 80.
    Cotten M, Schaffner G, Birnstiel ML:Ribozyme, antisense RNA, and antisense DNA inhibition of U7 small nuclear ribonucleoprotein-mediated histone pre-mRNA processing in vitro. Mol Cell Biol 1989,9: 4479–4487.PubMedGoogle Scholar
  81. 81.
    Larsson S, Hotchkiss G, Andang M, Nyholm T, Inzunza J, Jansson I, et al.:Reduced β2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res 1994,22: 2242–2248.PubMedCrossRefGoogle Scholar
  82. 82.
    Bertrand E, Grange T, Pictet R:Trans-acting hammerhead ribozymes in vivo. Present limits and future directions. In Gene Regulation: Biology of Antisense RNA and DNA. Edited by Erickson RP Izant JG. Raven Press: New York; 1992: 71–81.Google Scholar
  83. 83.
    Erickson RP, Lai L-W, Grimes J:Creating a conditional mutation of Wnt-1 by antisense transgenesis provides evidence that Wnt-1 is not essential for spermatogenesis. Dev Genet 1993,14: 274–281.PubMedCrossRefGoogle Scholar
  84. 84.
    Daugherty BL, Hotta K, Kumar C, Ahn YH, Zhu JD, Pestka S:Antisense RNA: effect of ribosome binding sites, target location, size, and concentration on the translation of specific mRNA molecules. Gene Anal Tech 1989,6: 1–16.PubMedCrossRefGoogle Scholar
  85. 85.
    Sullenger BA, Cech TR:Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 1993,262: 1566–1569.PubMedCrossRefGoogle Scholar
  86. 86.
    Cotten M, Birnstiel ML:Ribozyme mediated destruction of RNA in vivo. EMBO J 1989,8: 3861–3866.PubMedGoogle Scholar
  87. 87.
    Dropulic B, Lin NH, Martin MA, Jeang KT:Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression. J Virol 1992,66: 1432–41.PubMedGoogle Scholar
  88. 88.
    Sharp MGF, Mullins JJ:Novel approaches towards the nuclear expression of ribozyme and antisense RNA genes in transgenic mice. In Mechanisms and Applications of Gene Silencing. Edited by Lycett G, Tucker G, Grierson D. Nottingham: Nottingham University Press; 1995, in press.Google Scholar
  89. 89.
    Symons RH:Self-cleavage of RNA in the replication of small pathogens of plants and animals. Trends Biochem Sci 1989,14:445–450.PubMedCrossRefGoogle Scholar
  90. 90.
    Bruening G:Compilation of self-cleaving sequences from plant virus satellite RNAs and other sources. Methods Enzymol 1989,180:546–558.PubMedCrossRefGoogle Scholar
  91. 91.
    Symons RH:Small catalytic RNAs. Annu Rev Biochem 1992,61: 641–671.PubMedCrossRefGoogle Scholar
  92. 92.
    Haseloff J, Gerlach WL:Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus. Gene 1989,82: 43–52.PubMedCrossRefGoogle Scholar
  93. 93.
    Cotten M:The in vivo application of ribozymes. Trends Biotechnol 1990,8:174–178.PubMedCrossRefGoogle Scholar
  94. 94.
    Rossi JJ, Sarver N:RNA enzymes (ribozymes) as antiviral therapeutic agents. Trends Biotechnol 1990,8: 179–183.PubMedCrossRefGoogle Scholar
  95. 95.
    Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, et al.:Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990,247: 1222–1225.PubMedCrossRefGoogle Scholar
  96. 96.
    Bertrand E, Pictet R, Grange T:Can hammerhead ribozymes be efficient tools to inactivate gene-function? Nucleic Acids Res 1994,22: 293–300.PubMedCrossRefGoogle Scholar
  97. 97.
    Steinecke P, Herget T, Schreier PH:Expression of a chimeric ribozyme gene results in endonucleolytic cleavage of target mRNA and a concomitant reduction of gene expression in vivo. EMBO J 1992,11: 1525–1530.PubMedGoogle Scholar
  98. 98.
    Wegener D, Steinecke P, Herget T, Petereit I, Philipp C, Schreier PH:Expression of a reporter gene is reduced by a ribozyme in transgenic plants. Mol Gen Genet 1994,245: 465–470.PubMedCrossRefGoogle Scholar
  99. 99.
    Zhao JJ, Pick L:Generating loss-of-function phenotypes of the fushi tarazu gene with a targeted ribozyme in Drosophila. Nature 1993,365: 448–451.PubMedCrossRefGoogle Scholar
  100. 100.
    Heinrich J-C, Tabler M, Louis C:Attenuation of white gene expression in transgenic Drosophila melanogaster. Possible role of a catalytic antisense RNA. Dev Genet 1993,14: 258–265.PubMedCrossRefGoogle Scholar
  101. 101.
    Kilby NJ, Snaith MR, Murray JAH:Site-specific recombinases: tools for genome engineering. Trends Genet 1993,9: 413–421.PubMedCrossRefGoogle Scholar
  102. 102.
    Sauer B, Henderson N:Site-specific recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci USA 1988,85: 5166–5170.PubMedCrossRefGoogle Scholar
  103. 103.
    . O’Gorman S, Fox DT, Wahl GM:Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science 1991,251: 1351–1355.PubMedCrossRefGoogle Scholar
  104. 104.
    Lakso M, Sauer B, Mosinger BJ, Lee EJ, Manning RW, Yu SH, et al.:Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci USA 1992,89: 6232–6236.PubMedCrossRefGoogle Scholar
  105. 105.
    Orban PC, Chui D, Marth JD:Tissue- and site-specific DNA recombination in transgenic mice. Proc Natl Acad Sci USA 1992,89: 6861–6865.PubMedCrossRefGoogle Scholar
  106. 106.
    Herskowitz I:Functional inactivation of genes by dominant negative mutations. Nature 1987,329:219–222.PubMedCrossRefGoogle Scholar
  107. 107.
    Brand T, MacLellan WR, Schneider MD:A dominant negative receptor for type beta transforming growth factors created by deletion of the kinase domain. Biol Chem 1993,268: 11500–11503.Google Scholar
  108. 108.
    . Nagaya T, Jameson JL:Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance. J Biol Chem 1993,268: 15766–15771.PubMedGoogle Scholar
  109. 109.
    Ueno H, Colbert H, Escobedo JA, Williams LT:Inhibition of PDGF p receptor signal transduction by coexpression of a truncated receptor. Science 1991,152: 844–848.CrossRefGoogle Scholar
  110. 110.
    Amaya E, Musci TJ, Kirschner MW:Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos. Cell 1991,66: 257–270.PubMedCrossRefGoogle Scholar
  111. 111.
    Hemmati-Brivanlou A, Melton DA:A truncated activin receptor inhibits mesoderm induction and formation of axial structures in Xenopus embryos. Nature 1992,359: 609–614.PubMedCrossRefGoogle Scholar
  112. 112.
    Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, et al.:A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995,92: 5855–5859.PubMedCrossRefGoogle Scholar

Copyright information

© Rapid Science Publishers 1996

Authors and Affiliations

  • Matthew G. F. Sharp
  • John J. Mullins

There are no affiliations available

Personalised recommendations